Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Perrigo Company plc

A Comparative Analysis of SG&A Expenses: Alnylam Pharmaceuticals vs. Perrigo Company

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Alnylam Pharmaceuticals, Inc. and Perrigo Company plc from 2014 to 2023. Over this period, Alnylam's SG&A expenses surged by approximately 1,687%, reflecting its aggressive growth strategy and investment in market expansion. In contrast, Perrigo's expenses increased by about 89%, indicating a more stable, yet steadily growing operational cost structure.

By 2023, Perrigo's SG&A expenses were nearly 60% higher than Alnylam's, highlighting its larger scale of operations. This financial snapshot provides a window into the strategic priorities of these companies, with Alnylam focusing on rapid growth and Perrigo maintaining a steady course. Such insights are invaluable for investors and industry analysts alike, offering a glimpse into the financial health and strategic direction of these pharmaceutical giants.